Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects With Unexplained or Refractory Chronic Cough (RELIEF)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Camlipixant (Primary)
- Indications Cough
- Focus Proof of concept; Therapeutic Use
- Acronyms RELIEF
- Sponsors BELLUS Health
- 24 May 2023 Results from NCT03638180 , NCT03979638 and NCT04678206 evaluating the model-informed dose selection for phase 3 trials, presented at the 119th International Conference of the American Thoracic Society.
- 10 Nov 2021 According to a BELLUS Health media release, data from the study was presented at the European Respiratory Society International Congress 2021.
- 01 Nov 2021 According to a BELLUS Health media release, clinical evidence from this trial will be reviewed at the live webcast to be held on November 15, 2021.